5.1 C
London
Wednesday, April 24, 2024
HomeCoronavirusIndia bans export of drug being tested for coronavirus treatment

India bans export of drug being tested for coronavirus treatment

Date:

Related stories

Government bans wet wipes due to their adverse impact on environment

The British government announced on Monday, coinciding with Earth...

Infertility affects 48 million couples globally, environmental disrupters a major contributor

According to the World Health Organization (WHO), infertility is...

World Liver Day 2024: Take care of liver health with these food items

World Liver Day 2024 falls on Friday, April 19th....

Breast cancer may claim million lives per year by 2040: Lancet

BREAST CANCER is now the world’s most common carcinogenic...

Spring Covid booster vaccine bookings open in England

The National Health Service (NHS) in England is now...

India said on Wednesday it had banned the export of hydroxychloroquine and formulations of the malaria drug while experts test its efficacy in helping treat patients infected with coronavirus.

There are currently no approved treatments, or preventive vaccines for COVID-19, the highly contagious, sometimes deadly respiratory illness caused by coronavirus.

Researchers are studying existing treatments and working on experimental ones, but most current patients receive only supportive care such as breathing assistance.

Hydroxychloroquine, a malaria drug, is among the medications undergoing testing as a potential treatment for patients with the disease. Earlier this week, the American Society of Health-System Pharmacists (ASHP), which maintains a list of drug shortages, said there was a shortage of hydroxychloroquine.

“Chloroquine has demonstrated toxicity in certain patients,” Dinesh Dua, chairman of the Pharmaceuticals Export Promotion Council of India, told Reuters. “You have to tread with caution because there is no comprehensive data to prove it works.”

The group said India, the world’s largest supplier of generic drugs, was not short of the drug but that companies were acutely short of staff to run operations.

Cadila Healthcare Ltd, part of the Zydus group and one of India‘s top makers of the drug, said it was ramping up production to about 200 million pills a month.

“The priority is to work with the government in these challenging times and do all that we can in combating the coronavirus,” a spokesman said.

Earlier on Wednesday, Cadila Healthcare’s stock fell more than 5% after the export ban was announced.

Late on Tuesday, India ordered a 21-day lockdown of its 1.3 billion people to try to protect the world’s second most populous country from the fast-spreading coronavirus.

“It is impossible to maintain operations due to lockdown, because employees don’t want to come (to work),” Dua said.

India has already banned the export of ventilators, sanitizers and personal protection equipment such as masks and clothing used in the fight against the virus, which has so far infected more than 500 people and killed nine in the country.

The ban came after India this month curbed the export of 26 pharmaceutical ingredients and the medicines made from them, including Paracetamol – a common pain reliever also sold as acetaminophen – as the coronavirus outbreak plays havoc with supply chains.

Some of those restrictions have since been relaxed.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from up to 5 devices at once

Latest stories